Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Labcorp Holdings Inc. (NYSE:LH) Plans Quarterly Dividend of $0.72

Labcorp logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

Labcorp Holdings Inc. (NYSE:LH - Get Free Report) declared a quarterly dividend on Wednesday, October 21st. Shareholders of record on Tuesday, November 24th will be given a dividend of $0.72 per share by the medical research company on Friday, December 11th. This represents a $2.88 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, November 24th.

Labcorp has a payout ratio of 16.4% meaning its dividend is sufficiently covered by earnings. Research analysts expect Labcorp to earn $19.69 per share next year, which means the company should continue to be able to cover its $2.88 annual dividend with an expected future payout ratio of 14.6%.

Labcorp Trading Up 0.1%

Shares of Labcorp stock traded up $0.26 during mid-day trading on Wednesday, hitting $323.39. The stock had a trading volume of 566,716 shares, compared to its average volume of 689,293. The firm has a 50-day moving average of $320.55 and a two-hundred day moving average of $289.98. Labcorp has a 12-month low of $244.52 and a 12-month high of $341.80. The company has a quick ratio of 1.53, a current ratio of 1.80 and a debt-to-equity ratio of 0.69. The firm has a market cap of $26.23 billion, a P/E ratio of 26.75, a price-to-earnings-growth ratio of 1.82 and a beta of 0.87.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. During the same quarter in the previous year, the company earned $4.35 EPS. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Sell-side analysts forecast that Labcorp will post 18.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on LH shares. Robert W. Baird set a $352.00 target price on Labcorp in a research report on Friday, July 31st. UBS Group increased their price target on Labcorp from $361.00 to $380.00 and gave the stock a "buy" rating in a report on Friday, September 11th. Barclays raised their price objective on Labcorp from $320.00 to $330.00 and gave the stock an "equal weight" rating in a research report on Friday, September 11th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $306.00 price objective on shares of Labcorp in a report on Friday, July 31st. Finally, Wall Street Zen raised shares of Labcorp from a "hold" rating to a "buy" rating in a research report on Sunday, July 12th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Labcorp has a consensus rating of "Moderate Buy" and an average price target of $337.73.

Read Our Latest Stock Report on Labcorp

About Labcorp

(Get Free Report)

Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women's health testing, genetic testing, pathology services and other laboratory services.

Further Reading

Dividend History for Labcorp (NYSE:LH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Labcorp Right Now?

Before you consider Labcorp, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.

While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines